NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Patented Drug Delivery Platform Could Revolutionize Nicotine Delivery

January 25, 2019 16:19:48

Biotechnology company and drug delivery platform innovator Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) technology is patent protected for cannabidiol and all other nonpsychoactive cannabinoids. The company also currently has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. An article discussing the company reads, “Lexaria Bioscience has 10 patents granted with over 50 patents pending. Four of the granted patents focus on the delivery of nicotine. The company is not partnering with the tobacco industry. However, Bunka informed that Lexaria is exploring the potential use of its DehydraTECH technology to help people stop smoking. . . . The company’s technology has been shown to deliver nicotine to the brain quicker than traditional delivery systems. The goal for Lexaria is to put nicotine into some type of oral form to eliminate the need for inhalation and help people curb their smoking habits. DehydraTECH studies in 2018 included two animal studies that delivered pioneering results highlighting the improvements of nicotine delivery to blood plasma and across the blood-brain barrier (http://nnw.fm/4RGjQ). ”

To view the full article, visit http://nnw.fm/mWYh4

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and quicker onset of lipophilic active molecules. Lexaria has ten patents granted in the United States and Australia, and has filed over 50 patent applications worldwide across 10 patent families. Lexaria’s technology provides more rapid delivery to the bloodstream, as well as important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]